<DOC>
	<DOCNO>NCT01893905</DOCNO>
	<brief_summary>The main objective ass efficacy new formulation contain chondroitin sulfate glucosamine sulfate ( CS+GS ) compare placebo patient primary osteoarthritis knee .</brief_summary>
	<brief_title>Efficacy Safety New Formulation Chondroitin Sulfate Glucosamine Sulfate Treat Knee Osteoarthritis</brief_title>
	<detailed_description>The purpose study determine whether new combination chondroitin sulfate glucosamine sulfate administer day superior placebo treatment patient moderate severe knee osteoarthritis . Eligible patient ranzomized 1:1 treatment administer 24 week . Clinical efficacy end treatment evaluate . Safety evaluate adverse event recode study period .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Patient &gt; = 45 year . Primary OA knee accord ACR criterion . OA radiological grade IIIII accord Kellgren Lawrence . Patients moderatesevere pain . Patients clinical significant trauma surgery target knee . Concurrent arthritic disease ( antecedent and/or current sign ) could confound interfere evaluation pain efficacy chondrocalcinosis , Paget 's disease ipsilateral limb target knee , rheumatoid arthritis , aseptic osteonecrosis , gout , septic arthritis , ochronosis , acromegaly , haemochromatosis , Wilson 's disease , osteochondromatosis , seronegative spondyloarthropathy , mixed connective tissue disease , collagen vascular disease , psoriasis , inflammatory bowel disease fibromyalgia . Pain part body great knee pain could interfere evaluation . Subjects active acute chronic infection require antimicrobial therapy , serious viral ( e.g. , hepatitis , herpes zoster , HIV positivity ) fungal infection . Clinical diagnosis establish uncontrolled diabetes mellitus . Patients asthma . History hypersensitivity active drug excipients formulation .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>